Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
TrivarX Limited ( (AU:TRI) ) has provided an update.
TrivarX Limited has received Institutional Review Board approval for a clinical trial in collaboration with the Greater Los Angeles Veterans Research and Education Foundation and the US Department of Veterans Affairs. The trial will evaluate TrivarX’s single-channel ECG algorithm for screening major depressive episodes and sleep staging, potentially unlocking significant commercial opportunities for the company’s technology. The trial will involve 60 patients and is expected to conclude within 12 weeks, with patient enrolment beginning soon.
More about TrivarX Limited
TrivarX Limited is a mental health technology company that focuses on the early detection and screening of mental health conditions using objective measures. Founded in Australia, the company operates from offices in Perth and Minneapolis and is listed on the Australian Securities Exchange and the OTCQB Venture Market.
Technical Sentiment Signal: Buy
Current Market Cap: $4.39M
See more data about TRI stock on TipRanks’ Stock Analysis page.